Trial Profile
A Pilot Study Investigating the Effect of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers of Mullerian Origin
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Biomarker; Pharmacodynamics
- 16 Feb 2024 Status changed from active, no longer recruiting to completed.
- 05 Feb 2021 Planned End Date changed from 1 Apr 2020 to 1 Dec 2021.
- 24 May 2019 Status changed from recruiting to active, no longer recruiting.